Kaempferol Regulates the Lipid-Profile in High-Fat Diet-Fed Rats through an Increase in Hepatic PPARα Levels

Abstract

The aim of this study was to investigate the antiobesity and antihyperlipidemic effects of the flavonoid kaempferol (3,5,7,4′-tetrahydroxyflavone). After being fed a high-fat diet (HFD) for two weeks, rats were dosed orally with kaempferol (75, 150, or 300 mg/kg) or fenofibrate (100 mg/kg) once daily for eight weeks. Fenofibrate is an antilipemic agent that exerts its therapeutic effects through activation of peroxisome proliferator-activated receptor α (PPARα). Kaempferol (300 mg/kg/day) produced effects similar to fenofibrate in reducing body weight gain, visceral fat-pad weights, plasma lipid levels, as well as the coronary artery risk and atherogenic indices of HFD-fed rats. Kaempferol also caused dose-related reductions in hepatic triglyceride and cholesterol content and lowered hepatic lipid droplet accumulation and the size of epididymal adipocytes in HFD-fed rats. Kaempferol and fenofibrate reversed the HFD-induced downregulation of hepatic PPARα. HFD-induced reductions in the hepatic levels of acyl-CoA oxidase (ACO), and cytochrome P450 isoform 4A1 (CYP4A1) proteins were reversed by kaempferol and fenofibrate. The elevated expression of hepatic sterol regulatory element binding proteins (SREBPs) in HFD-fed rats were lowered by kaempferol and fenofibrate. These results suggest that kaempferol reduced the accumulation of visceral fat and improved hyperlipidemia in HFD-fed obese rats by increasing lipid metabolism through the downregulation of SREBPs and promoting the hepatic expression of ACO and CYP4A1, secondary to a direct upregulation hepatic PPARα expression.

Key words

kaempferol - high-fat diet - peroxisome proliferatoractivated receptor α - acyl-CoA oxidase - cytochrome P450 isoform 4A1

References

• 1 McCarthy M I. Genomics, type 2 diabetes, and obesity.  N Engl J Med. 2010;  363 2339-2350
• 2 Tilg H, Moschen A R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity.  Nat Rev Immunol. 2006;  6 772-783
• 3 Padwal R S, Majumdar S R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.  Lancet. 2007;  369 71-77
• 4 Nijveldt R J, van Nood E, van Hoorn D E, Boelens P G, van Norren K, van Leeuwen P A. Flavonoids: a review of probable mechanisms of action and potential applications.  Am J Clin Nutr. 2001;  74 418-425
• 5 Prince P S, Sathya B. Pretreatment with quercetin ameliorates lipids, lipoproteins and marker enzymes of lipid metabolism in isoproterenol treated cardiotoxic male Wistar rats.  Eur J Pharmacol. 2010;  635 142-148
• 6 Ong K C, Khoo H E. Effects of myricetin on glycemia and glycogen metabolism in diabetic rats.  Life Sci. 2000;  67 1695-1705
• 7 Sclafani A, Springer D. Dietary obesity in adult rats: similarities to hypothalamic and human obesity syndromes.  Physiol Behav. 1976;  17 461-471
• 8 van Heek M, Compton D S, France C F, Tedesco R P, Fawzi B, Graziano M P, Sybertz E J, Strader C D, Davis jr. H R. Diet-induced obese mice develop peripheral, but not central, resistance to leptin.  J Clin Invest. 1997;  99 385-390
• 9 Zhou J Y, Zhou S W, Zhang K B, Tang J L, Guang L X, Ying Y, Xu Y, Zhang L, Li D D. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.  Biol Pharm Bull. 2008;  31 1169-1176
• 10 Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 11 Abbott R D, Wilson P W, Kannel W B, Castelli W P. High density lipoprotein-cholesterol, total cholesterol screening and myocardial infarction. The Framingham Study.  Arterosclerosis. 1988;  8 207-211
• 12 Shanmugasundaram K R, Visvanathan A, Dhandapani K, Srinivasan N, Rasappan P, Gilbert R, Alladi S, Kancharla S, Vasanthi N. Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight.  Am J Clin Nutr. 1986;  44 805-815
• 13 Folch J, Lees M, Sloane-Stanley G H. A simple method for the isolation and purification of total lipids from animal tissues.  J Biol Chem. 1957;  226 497-506
• 14 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94 2467-2474
• 15 Park C H, Yamabe N, Noh J S, Kang K S, Tanaka T, Yokozawa T. The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice.  Biol Pharm Bull. 2009;  32 1734-1740
• 16 Mancini F P, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats.  FEBS Lett. 2001;  491 154-158
• 17 Björntorp P. Number and size of adipose tissue fat cells in relation to metabolism in human obesity.  Metabolism. 1971;  20 703-713
• 18 Paccaud F, Schlüter-Fasmeyer V, Wietlisbach V, Bovet P. Dyslipidemia and abdominal obesity: an assessment in three general populations.  J Clin Epidemiol. 2000;  53 393-400
• 19 Malloy M J, Kane J P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.  Adv Intern Med. 2001;  47 111-136
• 20 Libby P. Current concepts of the pathogenesis of the acute coronary syndromes.  Circulation. 2001;  104 365-372
• 21 Ansell B J, Watson K E, Fogelman A M, Navab M, Fonarow G C. High-density lipoprotein function recent advances.  J Am Coll Cardiol. 2005;  46 1792-1798
• 22 Hartog M G L, Feskens E J M, Hollman P C H, Katan M B, Kromhouy D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study.  Lancet. 1993;  342 1007-1011
• 23 Fang X K, Gao J, Zhu D N. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity.  Life Sci. 2008;  82 615-622
• 24 Mandard S, Muller M, Kersten S. Peroxisome proliferators-activated receptor alpha target genes.  Cell Mol Life Sci. 2004;  61 393-416
• 25 Hodge H C, Downs W L, Panner B S, Smith D W, Maynard E A. Oral toxicity and metabolism of diuron (N-(3,4-dichlorophenyl)-N′,N′-dimethylurea) in rats and dogs.  Food Chem Toxicol. 1967;  5 513-531
• 26 Fatehi-Hassanabad Z, Chan C. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic beta-cell function.  Nutr Metab. 2005;  2 1-12
• 27 Briggs M R, Yokoyama C, Wang X, Brown M S, Goldstein J L. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promotor. I. Identification of the protein and delineation of its target nucleotide sequence.  J Biol Chem. 1993;  268 14490-14496
• 28 Ginsberg H N. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.  J Clin Endocrinol Metab. 2006;  91 383-392
• 29 Park C H, Yamabe N, Noh J S, Kang K S, Tanaka T, Yokozawa T. The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice.  Biol Pharm Bull. 2009;  32 1734-1740